Article:Immunotherapy for Chronic Hepatitis B Virus Infection. (6143456)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Immunotherapy for Chronic Hepatitis B Virus Infection. and the publication date was 2018-09-15. The initial author is Antonio Bertoletti.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Gut and Liver

Immunotherapy for Chronic Hepatitis B Virus Infection

  • Antonio Bertoletti
  • Nina Le Bert

1Emerging Infectious Diseases Program, Duke-NUS Medical School, Singapore

2Viral Hepatitis Laboratory, Singapore Institute for Clinical Sciences, A*STAR, Singapore

Publication date (ppub): 9/2018

Publication date (epub): 1/2018


While new therapies for chronic hepatitis C virus infection have delivered remarkable cure rates, curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal. Although current direct antiviral therapies are very efficient in controlling viral replication and limiting the progression to cirrhosis, these treatments require lifelong administration due to the frequent viral rebound upon treatment cessation, and immune modulation with interferon is only effective in a subgroup of patients. Specific immunotherapies can offer the possibility of eliminating or at least stably maintaining low levels of HBV replication under the control of a functional host antiviral response. Here, we review the development of immune cell therapy for HBV, highlighting the potential antiviral efficiency and potential toxicities in different groups of chronically infected HBV patients. We also discuss the chronic hepatitis B patient populations that best benefit from therapeutic immune interventions.



In contrast to most communicable diseases, morbidity and mortality rates related to infection with hepatitis B virus (HBV) and hepatitis C virus (HCV) have increased over the last 20 years.[1] The two different viruses (HCV is an RNA virus belonging to Flaviviridae, while HBV is a DNA virus of the Hepadna-virus family) are both hepatotropic, noncytopathic, and able to establish persistent infections that cause different degrees of hepatic inflammations (chronic hepatitis) leading to the development of liver cirrhosis and hepatocellular carcinoma (HCC).

However, the therapeutic advances in their treatment have been radically different. New therapies for HCV have delivered remarkable results, with more than 90% of patients achieving viral clearance with all-oral treatment with directly acting antivirals.[2] In contrast, therapy options with curative intent for HBV are still a distant future[3] and thus new therapies, targeting either steps of HBV replication or the host immune system, are urgently needed.


Current treatments for chronic HBV infection (CHB) include pegylated-interferon-α (Peg-IFNα) and nucleos(t)ide analogues (NAs), but neither are suitably efficient in providing functional cure,[4] a virological and clinical situation defined by undetectable levels of hepatitis B surface antigen (HBsAg) and HBV DNA in the serum, normality of alanine aminotransferase (ALT) and development of hepatitis B surface antibody (anti-HBs). The term “functional cure” is thus used to define a virological situation in which, like in patients who resolved acute hepatitis B infection, HBV is not fully eliminated and few hepatocytes harbor covalently closed circular DNA (cccDNA) that is maintained under a repressed translational control by innate and adaptive immune mechanisms (NB, for an extended definition of functional cure in HBV we recommend[3]).

Peg-IFNα can achieve sustained off-treatment control, but only in a limited proportion of patients; approximately 10%. NAs therapy suppresses the production of new virions, reduces HBV DNA to undetectable levels in the serum and leads to a normalization of transaminases. However, loss of HBsAg is rarely achieved. Furthermore, since NAs suppress HBV replication by targeting at the level of DNA synthesis only, they are ineffective in their ability to eradicate the cccDNA, the episomal form of HBV from infected cells.[5] Treatment with NAs is thus considered lifelong with the potential risk of long-term toxicity,[6] with limited data on treatment withdrawal, which results in reactivation of HBV in the majority,[5] likely due to a defect on the restoration of anti-HBV immunity.


The rational of immune based approaches to achieve functional cure of HBV infection stems primarily from studies that have analyzed the profile of innate and adaptive immunity during HBV infection, but also from observations derived from HBV-infected patients under immunosuppressive treatment or bone marrow transplantation.[7],[8]

During natural HBV infection the innate immune system is poorly activated, due to an intrinsic ability of the virus to escape recognition. Readers are directed to these recent reviews for in depth description of such mechanism.[5],[9] Note however, that although acute and chronic HBV infections are associated with poor activation of innate immunity, HBV replication is efficiently suppressed by adequate innate immune triggering. Intracellular activation of retinoic acid-inducible gene-I (RIG-I)[10] or apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC)[11] pathways in HBV-infected hepatocytes are able to suppress HBV replication. Similarly, different cytokines such as IFNα,[12] IFNγ, tumor necrosis factor-α (TNFα), and interleukin-1β (IL-1β)[13],[14] produced by non-parenchymal cells of the liver can suppress, or even eradicate HBV from infected hepatocytes. The ability of innate cytokines to suppress HBV is also supported by the observation that co-infection with hepatotropic viruses able to activate innate immunity like HCV and hepatitis D virus, causes a drop of HBV replication.[15],[16] Thus, strategies aiming to activate these different components of innate immunity and to obtain for example a localized production of antiviral cytokines in the liver have been sought as possible immunological based therapies for HBV.[17]

The role of natural killer (NK) cells in HBV infection remains controversial with demonstration of a possible protective or pathogenic role.[18] The ability of IFNα therapies to control HBV replication has been linked with activation of NK cells[19] which can be also detected in patients who controlled acute HBV infection.[20],[21] However, at present it is not clear whether NK cells preferentially target HBV-infected hepatocytes or have a regulatory capacity on HBV-specific T cells.[22]

Similarly, even though anti-HBs antibodies have protective capacity and a defective humoral response has been implicated in HBV chronicity, the quantity and functionality of HBV-specific B cell responses during HBV infection is still poorly understood.[23] The reactivation of HBV replication in a proportion of B cell depleted patients treated with rituximab support a role in HBV control[24] and the therapeutic efficacy of anti-HBs antibody has been shown with HBV transgenic mice.[25]

The importance of T cells in establishing a functional cure of chronic HBV infection is instead a very established concept based on data obtained from patients and animal models. In chimpanzees acutely infected with HBV, deletion of CD8 T cells causes the establishment of a chronic HBV infection.[26] Patients with acute HBV infection mount a cellular anti-HBV immune response that is temporally correlated with HBV serum clearance.[27][29] However, HBV-specific T cells are quantitatively and functionally defective in CHB patients.[30] On the other hand, immunosuppressive treatments targeting cellular immunity in anti-hepatitis B core (anti-HBc) positive subjects often trigger rapid reactivation of HBV.[31] These data therefore indicate that virus specific T cells have the capacity to maintain HBV infection under tight replicative control.


Therapeutic strategies aimed at increasing innate immunity (Table 1, Fig. 1A) exploit the robust antiviral efficacy demonstrated by distinct cytokines (TNFα, IFNα, IFNγ and IL-1β)[13],[14],[32],[33] mimicking the activation of innate immunity during the early phase of acute HBV infection[20] and inducing a potent maturation of the adaptive immunity.[34],[35] Toll-like receptor (TLR) or RIG-I agonists have been developed to trigger activation of innate cytokines directly from hepatocytes (RIG-I)[36] or from neighboring immune cells (TLR-7 and TLR-8 agonists).[37] A TLR7 agonist (GS-9620) has been developed and demonstrated to induce IFNα production in plasmacytoid dendritic cells (pDCs). Oral administration of this compound induces a preferential activation of pDC in the gut and liver.[37] The drug administered to HBV-infected chimpanzees and woodchucks infected by woodchuck hepatitis B virus (WHBV) have shown a robust even though transient anti-HBV activity.[37],[38]

The compound has been also already tested in a phase I/ II clinical trial without side effect but scarce antiviral efficacy, likely due to the low dose used in patients (4 mg per patient compared to 1 mg/kg in chimpanzees).[39] New compounds with TLR-8 activity are also in development. TLR-8 agonists have been shown to be the most robust activator of pattern recognition receptors present in the intrahepatic environment.[40] Such compound should trigger a more robust IFNγ response in the liver in comparison to TLR-7 agonist thanks to its ability to activate IL-12 and IL-18 secretion from intrahepatic monocytes/ DCs.[40]

These cytokines can then activate intrahepatic NK and natural killer T cells, particularly mucosal associated invariant T (MAIT) cells that constitute a large proportion of T cells expressing NK markers in the human liver,[41] to produce large a quantity of IFNγ. In addition, IL-12 has been shown to boost the partial recovery of exhausted HBV-specific T cells[42] raising the possibility that such compounds might not only directly suppress HBV replication by triggering the production of antiviral cytokines but also by boosting the intrahepatic T cell response.

Other strategies to augment the innate immune response within the HBV-infected liver are to selectively direct different cytokines to HBV-infected hepatocytes (Table 1, Fig. 1A). For example a T cell receptor (TCR)-like antibody conjugated with IFNα has been shown to specifically target and deliver the antiviral cytokine to HBV-infected hepatocytes.[43]

The approach is to produce antibodies that are specific only for HBV-infected cells thanks to their ability to recognize the HBV-peptide/human leukocyte antigen (HLA)-complexes present on the surface of infected hepatocytes. Since these antibodies do not recognize HBV conformational antigens, they are not blocked by the high quantity of HBs or HBe antigens present in the serum of CHB patients and as such, target HBV-infected hepatocytes without the interference of HBV secretory antigens. In addition, they will not target other cells, like monocytes that have internalized these HBV antigens in CHB patients.[44] These antibodies have been shown to work in vitro but functional testing in animal model has not been performed yet.[45] A note of caution about these strategies designed to increase intrahepatic cytokines like IFNα or IL-12 is that these cytokines can also directly activate NK cells. We have pointed out above that NK activation might have a dual effect. They can directly target HBV-infected hepatocytes but also act as a rheostat to HBV-specific T cells. The possibility that activators of innate immunity might suppress HBV-specific immunity should be therefore considered.


The importance of specific T cell responses in the control of HBV replication have stimulated the development of strategies designed to enhance HBV-specific T cell responses in chronic HBV patients. Two strategies can be envisaged: one designed to boost the defective HBV-specific T cells still present in some chronic HBV patients, another one to engineer new HBV-specific T cells that can be adoptively transferred into patients (Table 1, Fig. 2).

Therapies based on the concept of boosting HBV-specific T cells present in limited numbers in patients with chronic HBV infection are primarily represented by therapies with checkpoint inhibitors (anti-programmed cell death-1 [PD-1], anti-CTLA-4, etc.) or therapeutic vaccines. Experimental data have shown that the function of peripheral and intrahepatic exhausted HBV-specific T cells[46],[47] can be partially restored in vitro by anti-PD1/PDL-1 blockade. However, at the moment, therapies with checkpoint inhibitors have been used successfully only in some solid malignancies such as lung, renal cell carcinoma and melanoma,[48],[49] with limited data in HCC and only reports of inadequate efficacy in chronic HCV patients[50] and in CHB patients with HCC.[51] Data are starting to emerge about a restricted but present antiviral activity of anti-PD1 therapy in CHB patients (see, but selection of patients, dose of anti-PD-1 antibodies and stage of chronic HBV infection are variables that can influence the efficacy and need to be investigated.

Vaccine therapies have already been used in several trials in chronic HBV patients (for a complete and detailed review see[52],[53]). Attempts to increase the quantity and function of antiviral T cells using different HBV vaccine compositions or activation of professional antigen presenting cells naturally loaded with HBV antigens[44] have shown some efficacy in vitro and in animal models.[54] However, initial trials with the use of classical prophylactic vaccines show suboptimal and conflicting results.[55][57] Moreover, attempts to use new vaccine formulations or combination therapies with antivirals have demonstrated only limited effect[58][60] in patients. Currently only a small trial of therapeutic vaccination in combination with anti-PD-1 infusion has shown good efficacy in woodchucks.[61] However, we need to remember that the extreme rarity of HBV-specific immune cells in chronic HBV patients, and their exhausted phenotype[46],[62][64] and metabolic alterations[65],[66] highlight the difficulty of boosting the existent HBV-specific T cells, particularly in the category of CHB that is more in need, hepatitis B e antigen positive (HBeAg+) patients with high levels of HBsAg and viral replication.

Therefore the development of strategies of immune restoration based on adoptive transfer of newly engineered HBV-specific T cells has emerged.[67] Clinical evidences are supporting this strategy since treatment of patients with leukemia and chronic HBV infection with bone marrow transplant from subjects with a HBV-specific T cell response (subjects vaccinated with HBV or subjects who have spontaneously controlled HBV infection)[7],[8] leads to HBV clearance. Similarly, transplantation of a HBV-infected liver into a subject with HBV-specific adaptive immunity resulted in subsequent HBV clearance[68] associated with an increase in HBV-specific cellular and humoral responses. Taken together, these data support the hypothesis that direct adoptive transfer of HBV-specific T cells in patients with chronic HBV infection might lead to HBV control.

For these reasons, design and expansion of differently engineered HBV-specific T cells for adoptive T cell transfer have been attempted. T cells able to recognize HBV-infected cells have been constructed using a chimeric antigen receptor made of an anti-HBs-specific antibody or using canonical HLA-class I restricted HBV-specific T cell receptors.[69][71] These cells are able to recognize HBV-infected targets in vitro and data from animal models[71] or selected clinical situations[72] are encouraging: HBV-specific TCR redirected T cells induce a substantial reduction of HBsAg in a patient where HBsAg was produced by HCC cells with HBV-DNA integration. Furthermore, new data in humanized chimeric mice carrying HBV-infected human hepatocytes demonstrated the ability of TCR-redirected T cells to recognize HBV-infected hepatocytes and cause a significant drop of HBV DNA.[73]

A major problem of adoptive T cell therapy is the practical difficulty in implementing them for clinical use.[74] The production of large quantities of engineered T cells is still cumbersome, strictly regulated and necessitates a laboratory with highly skilled personnel. New technology and methods are likely to progressively overcome these practical problems, but at the moment, such therapies remain only possible in a few laboratories.[75]

For these reasons, strategies that utilize antibodies with TCR-like specificities[45] or soluble TCR[76] able to redirect endogenous T cells against infected hepatocytes have also been proposed. The advantages of these approaches are that they do not require manipulation of T cells outside the patient’s body. The antibodies or the soluble TCR, designed to induce specific accumulation and triggering of endogenous T cells in close contact to their specific targets, can be injected directly into the patients. At the moment, such strategy has been used with success in human immunodeficiency virus infections (soluble TCR)[77] while TCR-like antibodies have been only used to deliver cytokine payloads directly towards HBV-infected targets.[43]


The therapeutic strategies designed to boost host immunity and in particular HBV-specific T cells in patients with chronic HBV infection carry the inherent risk of inducing severe liver inflammatory events. Since the liver is an organ essential for life, such risk needs to be carefully managed.

HBV is a non-cytopathic virus; CD8 T cells are essential for viral control but in addition to lyses of HBV-infected hepatocytes, they can trigger liver inflammation.[78],[79] It is however difficult to predict the extent of liver damage that a specific number of HBV-specific CD8 T cells can induce. Liver inflammation is not only related to the quantity and fitness of restored HBV-specific CD8 T cells (i.e., by checkpoint inhibitors therapy) or adoptively transferred engineered HBV-specific T cells but also to the modification of the liver environment induced by the chronic infection. Human studies performed to quantify the number of HBV-specific CD8 T cells in different clinical situations have for example clearly demonstrated that a direct proportionality between HBV-specific CD8 T cells and extent of liver damage is observed only in patients with acute hepatitis.[29] Such direct correlation does not exist in chronic HBV patients where liver damage is related to the ability of HBV-specific CD8 T cells to trigger the recruitment of inflammatory cells.[80] Furthermore, it has been recently shown that similar numbers of HBV-specific T cells can be demonstrated in chronic HBV patients with active hepatitis or in those with a complete absence of liver inflammatory events.[81],[82] In addition, high frequencies of liver resident HBV-specific T cells were found in subjects with normal liver, showing that intrahepatic HBV-specific T cell can have pure protective ability and are not correlated with the extent of liver damage.[83]

The causes of why liver inflammatory patterns cannot be directly correlated with the quantity of HBV-specific T cells are not completely clear, but it is instead certain that several variables can modulate both liver inflammatory events and T cell fitness. For example, release of arginase directly from hepatocytes or from myeloid suppressor cells has been shown to dampen T cell function.[84][86] Equally, NK cells[18] or regulatory cells[87] present in the liver might inhibit T cell function or suppress inflammatory events while chronic liver inflammation might block the access of T cells to their targets by altering the normal anatomy of liver endothelial cells. On the other hand, liver inflammatory events can profoundly alter the population of intrahepatic myeloid cells. The recruitment of inflammatory monocytes might alter the normal tolerogenic environment of the liver, characterized by the presence of Kupffer cells with tolerogenic and anti-inflammatory features,[88] to a more pro-inflammatory environment. We have recently demonstrated an enrichment of inflammatory monocytes in the intrahepatic environment of patients with advanced liver pathologies.[89] These myeloid cells do not carry the classical anti-inflammatory features of resident intrahepatic monocytes (Kupffer cells), but are constantly producing inflammatory cytokines trough activation with bacterial products.[89] It might be hypothesized that activation of HBV-specific CD8 T cells in an environment rich of such inflammatory myeloid cells will initiate a more severe inflammation of the liver. In other words, similar levels of CD8 T cells responses in different liver microenvironments would trigger different degrees of liver inflammation (Fig. 3). The risk of inducing severe liver damage through the use of immune therapy is therefore still difficult to predict. It can be potentially managed by a careful selection of CHB patient populations, but research efforts need to be boosted to understand which is the liver environment that can better support an exogenous activation of innate or adaptive intrahepatic immunity.

One other strategy to reduce the risk of liver toxicities is to develop approaches with lower ability to trigger inflammatory events. Indeed, if the restoration of HBV-specific T cell response in chronic HBV patients through checkpoint inhibitors or vaccines is difficult to modify or predict and would be related to the quantity of exhausted T cells present in the distinct groups of patients, adoptive T cell transfer can be performed with engineered HBV-specific CD8 T cells with reduced ability to trigger inflammatory events. One of these strategies is based on the utilization of T cells engineered to only transiently express HBV-specific TCRs through non-viral gene transfer systems. T cells transduced by viral vectors stably express the TCRs, and their unchecked expansion might lead to progressive liver toxicities that is difficult to manage clinically. To bypass this problem, we implemented a strategy where T cells are engineered through messenger RNA (mRNA) electroporation and they express HBV-specific TCRs for only 3 to 5 days.[90] In addition, to circumvent safety concerns related to stable genetic manipulation of T cells induced by viral vectors, these cells with limited life-span can be adoptively transferred in escalating doses and their potential toxicities are more easily managed than stably transduced TCR-redirected T cells. Despite their transient expression of TCRs, mRNA TCR-redirected T cells control the expansion of HBV-expressing hepatoma cells in mice.[90] Furthermore, the antiviral activity of mRNA TCR-redirected T cells was also recently tested in an HBV-infected human liver chimeric uPA/SCID/ILγR2 (USG) mouse model.[73] These mRNA TCR-redirected T cells were shown to preferentially home to the liver of HBV-infected mice and induced a progressive but timely controlled virus-specific immune-mediated reduction of serological and intrahepatic HBV viral loads (~1 to 1.5 log reduction of HBV DNA after 3 doses of 0.5 million T cells).

Importantly, mRNA TCR-redirected T cells trigger only a temporary immune-mediated killing of the infected hepatocytes. Ten days after infusion the treated mice show a reversion of transaminase levels identical to the ones detected prior to therapy. Such data are important for the clinical translation of T cell therapy into patients, since the temporary effect of mRNA TCR-redirected T cells will permit a safe implementation of dose escalating regimes. This could allow the optimization of dose and therapy length required to achieve substantial reduction of HBV-infected hepatocytes without triggering severe inflammatory events that should subside when the expression of HBV-specific TCRs disappear from the adoptively transferred T cells. The flexibility of such cell preparation will also allow to study possible combination therapy with drugs suppressing HBV replication (NAs) or blocking hepatocyte re-infection and intrahepatic spreading of HBV (Myrcludex-B).[91]


Current guidelines for hepatitis B indicate that antiviral therapy should be reserved until the appearance of clinically active liver disease or the development of fibrosis. The rationale of such an approach is based on three main suppositions: (1) the initial stage of CHB infection defined as “immune tolerant” (now defined as HBeAg+ chronic infection) is a fully benign without any relevant pathological consequences; (2) only CHB patients that have active inflammation are eligible for therapy; and (3) the elevation in transaminase levels is a sign of an “awakening” of the host immune response. Although the premise on which these points are based on are not completely incorrect, we can now better define their clinical and immunological significance based on new recent data.

The first point to consider is whether the initial phase of disease is really devoid of pathological consequences and if we should wait to treat patients with chronic HBV infection until active liver inflammation occurs. We have recently demonstrated that patients in the early stages of infection exhibit already high levels of HBV DNA integration and clonal hepatocyte expansion, which may be a risk factor for HCC.[82] Studies have also shown that the incidence of HCC and cirrhosis is seen to increase with elevated levels of HBV DNA; moreover HBV DNA level, irrespective of biochemical activity, is a strong predictor of HCC.[92] These data, therefore provide weight to the argument for earlier treatment of patients with chronic HBV[93] in order to treat not only the liver inflammation but also for the prevention of liver cancer.

The second consideration is that ALT levels are not a surrogate measure of the virus-specific T cell response. In adenovirus infected mice, T cell immunity against hepatocytes was detected without an elevation of transaminase levels.[94] In CHB patients, the quantity of circulating and intrahepatic HBV-specific T cells is not proportional to the level of biochemical activity.[80],[95] In addition, young CHB patients considered “immune tolerant” (low ALT and very high levels of HBV DNA) have a repertoire and function of HBV-specific T cells that is similar to the one of patients with chronic active hepatitis (high ALT levels and high HBV DNA).[81] Thus the difference between chronic HBV patients with either low or high levels of ALT is their level of intrahepatic inflammatory cells (inflammatory monocytes, non HBV-specific T cells, NK cells) and not their level of HBV-specific immunity. Patients with a higher level of ALT might be more prone to developing an inflammatory response. Importantly, basic immunological studies comparing immune profiles of humans at different ages have shown that pro-inflammatory responses increase proportionally with age.[96] As such it might be true that older patients with chronic active hepatitis have a more “awakened” host immune response, but such an “increased” immune response is certainly not HBV-specific, but it is the result of a more general trend to start and maintain an intrahepatic inflammatory reaction which increases with age.[97]

Therefore, we would argue that the new immunological therapies designed to boost innate or adaptive immunity in patients with chronic HBV infection (Fig. 1), might be better suited for treating young patients in the so called “immune tolerant” phase of the disease, now redefined as HBeAg+ infection, than older subjects with chronic active hepatitis B (now better defined as HBeAg+ hepatitis, EASL guidelines[98]) (Fig. 3). Our argument centers around the point that, in immunological terms, younger subjects have less compromised HBV-specific T cell function and a lower “pro-inflammatory response” than older subjects and for this reason they might be more likely to recover their HBV-specific T cell immunity and less likely develop a severe inflammatory reaction in the liver (see also[97]).

Another important consideration is that, as we have already pointed out, the presence of an inflammatory infiltrate may in fact lead to the inhibition of the HBV-specific responses that immunological therapies would like to boost. TNFα, released by inflammatory monocytes that are increased in the advanced phase of chronic hepatitis B,[89] can directly inhibit virus-specific T cells.[99] Furthermore, the intrahepatic environment of patients with chronic active hepatitis is not conducive for antigen-specific immune function. It is enriched with regulatory immune cells (T-regs, myeloid derived suppressor cells, NK cells) that can suppress not only the inflammatory response but also HBV-specific T cells. In addition, arginase, the enzyme released by dying hepatocytes, deprive the liver environment of arginine, an essential amino acid for virus-specific T cell function.[84][86] In this regard, treating patients with lower levels of inflammation (or indeed lower ALT) may achieve a more beneficial outcome. In keeping with this, a small study by Gotto et al.[100] showed that treatment with steroids, as a means of immunosuppression, to dampen the inflammatory infiltrate prior to NA initiation, in fact resulted in an increase of HBV-specific T cells. Furthermore, it is interesting to note that successful vaccine therapies in woodchucks with persistent WHBV infection were seen in animals with low or absent liver inflammatory events.[54] In this context, it should also be noted that the addition of NA therapy, to decrease not only HBV DNA levels but also intrahepatic inflammatory events, might be beneficial.

Therefore, taking these data into account, it is likely that even at a similar elevated level of HBV DNA, patients with lower ALT levels, and/or of younger age may respond better to immunological based treatment. As these patients, considered immune tolerant, are usually excluded from the treatment pool, there is a paucity of data on the outcome of traditional treatment in this cohort. However, even with the few studies performed, data actually show that such patients are not at all less likely to respond to treatment. A study by Carey et al.[101] showed for example that “immune tolerant” children treated with a combination of NA (Lamivudine) and Peg-IFNα demonstrated evidence of HBsAg loss associated with increased HBV-specific T cell proliferation early during therapy.


New immune therapies, currently in the pipeline, are supported by strong scientific rational but their efficacy in the real life setting remains to be seen. The risk of inducing severe liver inflammation has so far restricted direct clinical testing. We argued here that new methods of T cell engineering and criteria of CHB patient selection for immunotherapy should be revised, and such options can open new and safer avenues to test these new immunotherapeutic approaches.


  1. JD StanawayAD FlaxmanM NaghaviThe global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013Lancet20163881081108810.1016/S0140-6736(16)30579-727394647
  2. GR FosterN AfdhalSK RobertsSofosbuvir and velpatasvir for HCV genotype 2 and 3 infectionN Engl J Med20153732608261710.1056/NEJMoa151261226575258
  3. RG GishBD GivenCL LaiChronic hepatitis B: virology, natural history, current management and a glimpse at future opportunitiesAntiviral Res2015121475810.1016/j.antiviral.2015.06.00826092643
  4. TM BlockR GishH GuoChronic hepatitis B: what should be the goal for new therapies?Antiviral Res201398273410.1016/j.antiviral.2013.01.00623391846
  5. F ZoulimF LebosséM LevreroCurrent treatments for chronic hepatitis B virus infectionsCurr Opin Virol20161810911610.1016/j.coviro.2016.06.00427318098
  6. US GillA ZissimopoulosS Al-ShammaAssessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?J Infect Dis201521137438210.1093/infdis/jiu47125156561
  7. Y IlanA NaglerR AdlerAdoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantationHepatology1993182462528340054
  8. GK LauAS LokRH LiangClearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transferHepatology1997251497150110.1002/hep.5102506319185774
  9. MK MainiAJ GehringThe role of innate immunity in the immunopathology and treatment of HBV infectionJ Hepatol2016641 SupplS60S7010.1016/j.jhep.2016.01.02827084038
  10. S SatoK LiT KameyamaThe RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virusImmunity20154212313210.1016/j.immuni.2014.12.01625557055
  11. J LuciforaY XiaF ReisingerSpecific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNAScience20143431221122810.1126/science.124346224557838
  12. L BelloniL AllweissF GuerrieriIFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccD-NA minichromosomeJ Clin Invest201212252953710.1172/JCI5884722251702
  13. H McClaryR KochFV ChisariLG GuidottiRelative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokinesJ Virol2000742255226410.1128/JVI.74.5.2255-2264.200010666256
  14. K WatashiG LiangM IwamotoInterleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deami-nase (AID)J Biol Chem2013288317153172710.1074/jbc.M113.50112224025329
  15. YF LiawYC ChenIS SheenRN ChienCT YehCM ChuImpact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infectionGastroenterology20041261024102910.1053/j.gastro.2004.01.01115057742
  16. E SagnelliN CoppolaV MessinaHBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical courseHepatology2002361285129110.1053/jhep.2002.3650912395342
  17. A BertolettiL RivinoHepatitis B: future curative strategiesCurr Opin Infect Dis20142752853410.1097/QCO.000000000000011025304392
  18. MK MainiD PeppaNK cells: a double-edged sword in chronic hepatitis B virus infectionFront Immunol201345710.3389/fimmu.2013.0005723459859
  19. R ThimmeM DandriDissecting the divergent effects of interfer-on-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?J Hepatol20135820520910.1016/j.jhep.2012.11.00723159772
  20. P FisicaroC ValdattaC BoniEarly kinetics of innate and adaptive immune responses during hepatitis B virus infectionGut20095897498210.1136/gut.2008.16360019201769
  21. GJ WebsterS ReignatMK MainiIncubation phase of acute hepatitis B in man: dynamic of cellular immune mechanismsHepatology2000321117112410.1053/jhep.2000.1932411050064
  22. D PeppaUS GillG ReynoldsUp-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletionJ Exp Med20132109911410.1084/jem.2012117223254287
  23. B OlivieroA CerinoS VarchettaEnhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infectionsJ Hepatol201155536010.1016/j.jhep.2010.10.01621145853
  24. W YeoTC ChanNW LeungHepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximabJ Clin Oncol20092760561110.1200/JCO.2008.18.018219075267
  25. TY ZhangQ YuanJH ZhaoProlonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigenGut20166565867110.1136/gutjnl-2014-30896426423112
  26. R ThimmeS WielandC SteigerCD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infectionJ Virol200377687610.1128/JVI.77.1.68-76.200312477811
  27. C FerrariA PennaA BertolettiCellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infectionJ Immunol1990145344234492230128
  28. A PennaFV ChisariA BertolettiCytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigenJ Exp Med19911741565157010.1084/jem.174.6.15651720813
  29. MK MainiC BoniGS OggDirect ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infectionGastroenterology19991171386139610.1016/S0016-5085(99)70289-110579980
  30. A BertolettiC FerrariAdaptive immunity in HBV infectionJ Hepatol2016641 SupplS71S8310.1016/j.jhep.2016.01.02627084039
  31. D ShouvalO ShiboletImmunosuppression and HBV reactivationSemin Liver Dis20133316717710.1055/s-0033-134572223749673
  32. SF WielandLG GuidottiFV ChisariIntrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic miceJ Virol2000744165417310.1128/JVI.74.9.4165-4173.200010756029
  33. R PuroRJ SchneiderTumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNAJ Virol2007817351736210.1128/JVI.00554-0717475655
  34. A BertolettiAJ GehringImmune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?PLoS Pathog20139e100378410.1371/journal.ppat.100378424367255
  35. F ZoulimS LuangsayD DurantelTargeting innate immunity: a new step in the development of combination therapy for chronic hepatitis BGastroenterology20131441342134410.1053/j.gastro.2013.04.02823710602
  36. F GuoY HanX ZhaoSTING agonists induce an innate antiviral immune response against hepatitis B virusAntimicrob Agents Chemother2015591273128110.1128/AAC.04321-1425512416
  37. RE LanfordB GuerraD ChavezGS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzeesGastroenterology20131441508151710.1053/j.gastro.2013.02.00323415804
  38. S MenneDB TumasKH LiuSustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the woodchuck model of chronic hepatitis BJ Hepatol2015621237124510.1016/j.jhep.2014.12.02625559326
  39. EJ GaneYS LimSC GordonThe oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infectionJ Hepatol20156332032810.1016/j.jhep.2015.02.03725733157
  40. J JoAT TanJE UssherToll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liverPLoS Pathog201410e100421010.1371/journal.ppat.100421024967632
  41. XZ TangJ JoAT TanIL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cellsJ Immunol20131903142315210.4049/jimmunol.120321823447689
  42. A SchurichLJ PallettM LubowieckiThe third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 T cellsPLoS Pathog20139e100320810.1371/journal.ppat.100320823516358
  43. C JiKS SastryG TiefenthalerTargeted delivery of interferon-alpha to hepatitis B virus-infected cells using T-cell receptor-like antibodiesHepatology2012562027203810.1002/hep.2587522684948
  44. AJ GehringM HaniffaPT KennedyMobilizing monocytes to cross-present circulating viral antigen in chronic infectionJ Clin Invest20131233766377610.1172/JCI6604323908113
  45. KS SastryCT TooK KaurTargeting hepatitis B virus-infected cells with a T-cell receptor-like antibodyJ Virol2011851935194210.1128/JVI.01990-1021159876
  46. C BoniP FisicaroC ValdattaCharacterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infectionJ Virol2007814215422510.1128/JVI.02844-0617287266
  47. P FisicaroC ValdattaM MassariAntiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis BGastroenterology201013868269310.1053/j.gastro.2009.09.05219800335
  48. AI DaudK LooML PauliTumor immune profiling predicts response to anti-PD-1 therapy in human melanomaJ Clin Invest20161263447345210.1172/JCI8732427525433
  49. DT LeJN UramH WangPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med20153722509252010.1056/NEJMoa150059626028255
  50. MJ FullerB CallendretB ZhuImmunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1)Proc Natl Acad Sci U S A2013110150011500610.1073/pnas.131277211023980172
  51. AB El-KhoueiryB SangroT YauNivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialLancet20173892492250210.1016/S0140-6736(17)31046-228434648
  52. ML MichelQ DengM Mancini-BourgineTherapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challengesJ Hepatol2011541286129610.1016/j.jhep.2010.12.03121238516
  53. J LiuA KosinskaM LuM RoggendorfNew therapeutic vaccination strategies for the treatment of chronic hepatitis BVirol Sin201429101610.1007/s12250-014-3410-524452539
  54. AD KosinskaE ZhangL JohrdenCombination of DNA prime: adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck modelPLoS Pathog20139e100339110.1371/journal.ppat.100339123785279
  55. ML MichelS PolC BrechotP TiollaisImmunotherapy of chronic hepatitis B by anti HBV vaccine: from present to futureVaccine2001192395239910.1016/S0264-410X(00)00461-811257367
  56. M Mancini-BourgineH FontaineD Scott-AlgaraS PolC BréchotML MichelInduction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriersHepatology20044087488210.1002/hep.2040815382173
  57. P VandepapelièreGK LauG Leroux-RoelsTherapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudineVaccine2007258585859710.1016/j.vaccine.2007.09.07218031872
  58. DZ XuXY WangXL ShenResults of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findingsJ Hepatol20135945045610.1016/j.jhep.2013.05.00323669281
  59. O GodonH FontaineS KahiImmunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analoguesMol Ther20142267568410.1038/mt.2013.27424394187
  60. AS LokCQ PanSH HanRandomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis BJ Hepatol20166550951610.1016/j.jhep.2016.05.01627210427
  61. J LiuE ZhangZ MaEnhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infectionPLoS Pathog201410e100385610.1371/journal.ppat.100385624391505
  62. W WuY ShiS LiBlockade of Tim-3 signaling restores the virus-specific CD8+ T-cell response in patients with chronic hepatitis BEur J Immunol2012421180119110.1002/eji.20114185222539292
  63. PD KurktschievB RaziorrouhW SchrautDysfunctional CD8+ T cells in hepatitis B and C are characterized by a lack of antigen-specific T-bet inductionJ Exp Med20142112047205910.1084/jem.2013133325225458
  64. B BengschB MartinR ThimmeRestoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiationJ Hepatol2014611212121910.1016/j.jhep.2014.07.00525016223
  65. A SchurichLJ PallettD JajbhayDistinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same hostCell Rep2016161243125210.1016/j.celrep.2016.06.07827452473
  66. P FisicaroV BariliB MontaniniTargeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis BNat Med20172332733610.1038/nm.427528165481
  67. S KohA BertolettiCircumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response?Med Microbiol Immunol2015204879410.1007/s00430-014-0377-725511870
  68. E LoggiF BihlJV Chisholm 3rdAnti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graftJ Hepatol20095062563010.1016/j.jhep.2008.08.02619157623
  69. F BohneM ChmielewskiG EbertT cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytesGastroenterology200813423924710.1053/j.gastro.2007.11.00218166356
  70. AJ GehringSA XueZZ HoEngineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell linesJ Hepatol20115510311010.1016/j.jhep.2010.10.02521145860
  71. K KrebsN BöttingerLR HuangT cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in miceGastroenterology201314545646510.1053/j.gastro.2013.04.04723639914
  72. W QasimM BrunettoAJ GehringImmunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patientJ Hepatol20156248649110.1016/j.jhep.2014.10.00125308176
  73. J KahS KohT VolzLymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infectionJ Clin Invest20171273177318810.1172/JCI9302428737510
  74. CH JuneBR BlazarJL RileyEngineering lymphocyte subsets: tools, trials and tribulationsNat Rev Immunol2009970471610.1038/nri263519859065
  75. AD KaiserM AssenmacherB SchröderTowards a commercial process for the manufacture of genetically modified T cells for therapyCancer Gene Ther201522727810.1038/cgt.2014.7825613483
  76. J OatesNJ HassanBK JakobsenImmTACs for targeted cancer therapy: why, what, how, and whichMol Immunol2015672 Pt A677410.1016/j.molimm.2015.01.02425708206
  77. H YangS BuissonG BossiElimination of latently HIV-infected cells from antiretroviral therapy-suppressed subjects by engineered immune-mobilizing T-cell receptorsMol Ther2016241913192510.1038/mt.2016.11427401039
  78. G SitiaM IsogawaM IannaconeIL CampbellFV ChisariLG GuidottiMMPs are required for recruitment of antigen-nonspecific mononuclear cells into the liver by CTLsJ Clin Invest20041131158116710.1172/JCI20042108715085195
  79. K AndoT MoriyamaLG GuidottiMechanisms of class I restricted immunopathology: a transgenic mouse model of fulminant hepatitisJ Exp Med19931781541155410.1084/jem.178.5.15418228807
  80. MK MainiC BoniCK LeeThe role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infectionJ Exp Med20001911269128010.1084/jem.191.8.126910770795
  81. PT KennedyE SandalovaJ JoPreserved T-cell function in children and young adults with immune-tolerant chronic hepatitis BGastroenterology201214363764510.1053/j.gastro.2012.06.00922710188
  82. WS MasonUS GillS LitwinHBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerantGastroenterology201615198699810.1053/j.gastro.2016.07.01227453547
  83. LJ PallettJ DaviesEJ ColbeckIL-2(high) tissue-resident T cells in the human liver: Sentinels for hepatotropic infectionJ Exp Med20172141567158010.1084/jem.2016211528526759
  84. LJ PallettUS GillA QuagliaMetabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cellsNat Med20152159160010.1038/nm.385625962123
  85. E SandalovaD LaccabueC BoniIncreased levels of arginase in patients with acute hepatitis B suppress antiviral T cellsGastroenterology2012143788710.1053/j.gastro.2012.03.04122475535
  86. A DasM HoareN DaviesFunctional skewing of the global CD8 T cell population in chronic hepatitis B virus infectionJ Exp Med20082052111212410.1084/jem.2007207618695005
  87. D XuJ FuL JinCirculating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis BJ Immunol200617773974710.4049/jimmunol.177.1.73916785573
  88. G SitiaM IannaconeR AiolfiKupffer cells hasten resolution of liver immunopathology in mouse models of viral hepatitisPLoS Pathog20117e100206110.1371/journal.ppat.100206121655107
  89. A Tan-GarciaLE WaiD ZhengIntrahepatic CD206(+) macrophages contribute to inflammation in advanced viral-related liver diseaseJ Hepatol20176749050010.1016/j.jhep.2017.04.02328483682
  90. S KohN ShimasakiR SuwanaruskA practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virusMol Ther Nucleic Acids20132e11410.1038/mtna.2013.4323941866
  91. J PetersenM DandriW MierPrevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope proteinNat Biotechnol20082633534110.1038/nbt138918297057
  92. CJ ChenHI YangJ SuRisk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA levelJAMA2006295657310.1001/jama.295.1.6516391218
  93. F ZoulimWS MasonReasons to consider earlier treatment of chronic HBV infectionsGut20126133333610.1136/gutjnl-2011-30093722147510
  94. D StabenowM FringsC TrückBioluminescence imaging allows measuring CD8 T cell function in the liverHepatology2010511430143710.1002/hep.2357520373369
  95. GJ WebsterS ReignatD BrownLongitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapyJ Virol2004785707571910.1128/JVI.78.11.5707-5719.200415140968
  96. TR KollmannO LevyRR MontgomeryS GorielyInnate immune function by Toll-like receptors: distinct responses in newborns and the elderlyImmunity20123777178310.1016/j.immuni.2012.10.01423159225
  97. A BertolettiPT KennedyThe immune tolerant phase of chronic HBV infection: new perspectives on an old conceptCell Mol Immunol20151225826310.1038/cmi.2014.7925176526
  98. European Association for the Study of the LiverEASL 2017 clinical practice guidelines on the management of hepatitis B virus infectionJ Hepatol20176737039810.1016/j.jhep.2017.03.02128427875
  99. M BeyerZ AbdullahJM ChemnitzTumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infectionNat Immunol20161759360310.1038/ni.339926950238
  100. J GottoGJ WebsterD BrownJ JenkinsGM DusheikoA BertolettiThe impact of HBV-DNA fluctuations on virus-specific CD8+ T cells in HBeAg+ chronic hepatitis B patients treated with a steroid and lamivudineJ Viral Hepat20061341542510.1111/j.1365-2893.2005.00716.x16842445
  101. I CareyL D’AntigaS BansalImmune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapyJ Virol2011852416242810.1128/JVI.01449-1021147914
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution-NonCommercial. The main subject has been identified as hepatitis B.